Academic trials
Lung cancer researchers across the Nordics have collaborated for a long time, primarily through ad-hoc initiatives driven by personal engagement.
Over the years, this collaboration has led to several significant academic trials and projects. The table below lists selected examples with patient category, participating countries, and key citations or clinical trial registrations.
Country abbreviations: NO, Norway. DK, Denmark. SE, Sweden. FI, Finland.
| Study name | Patient category | Countries | Key citations / clinical trials |
|---|---|---|---|
| NARLAL | Curative radiotherapy | DK / NO | DOI: 10.1016/j.ijrobp.2013.03.035 |
| NARLAL2 | Locally advanced NSCLC, curative radiotherapy dose escalation | DK / NO / SE | DOI: 10.1080/0284186X.2017.1366049 |
| TREM | EGFR-positive | NO / DK / SE / FI | DOI: 10.1016/j.lungcan.2020.03.009 |
| FIOL | EGFR-positive | NO / DK / SE | DOI: 10.21037/tlcr-21-995 |
| SOLUCOM | KRAS-positive | NO / DK / SE | NCT05311709 |
| Thora | SCLC-LS | NO / SE / DK | DOI: 10.1016/S1470-2045(20)30742-7 |
| ACHILES | Limited-disease SCLC | NO / DK / SE | NCT03540420 |
| TRIPLEX | SCLC-LS | NO / SE / DK | NCT05223647 |
| Asteroid | Curative radiotherapy | NO / SE / DK | NCT03446547 |
| Hilus | Curative radiotherapy | NO / SE / DK | DOI: 10.1016/j.jtho.2021.03.019 |
| Space | Curative radiotherapy | NO / SE | DOI: 10.1016/j.radonc.2016.08.015 |
| NIELS | Limited-disease SCLC, radiotherapy planning QA | Nordic | DOI: 10.1016/j.radonc.2025.110946 |
| ScanLeaf | Epidemiology | NO / SE / DK | DOI: 10.1016/j.jtocrr.2021.100165 |
| TNM-I | Translational | NO / SE / DK | DOI: 10.1158/1078-0432.CCR-14-1905 |
Doctoral theses on lung cancer and thoracic oncology in the Nordic countries
A working bibliography of PhD theses from Nordic institutions relevant to lung cancer, non-small cell lung cancer, small cell lung cancer, mesothelioma, and adjacent thoracic oncology.
Editorial note.
Repository records and university thesis pages are preferred as primary sources. Person profiles,
defence announcements, and press releases are included when no direct repository record has yet
been identified. Research-group, supervisor, opponent, or lineage references are treated only as
contextual historical notes and should not be interpreted as formal academic genealogy, endorsement,
or quality ranking.
Scope and inclusion criteria
This list includes doctoral theses from Denmark, Finland, Iceland, Norway, and Sweden. The core scope is lung cancer, especially NSCLC, but selected theses on SCLC, mesothelioma, pulmonary metastases, radiotherapy-related lung cancer risk, diagnostic pathways, screening, and thoracic oncology methods are included when they are historically or clinically relevant.
How to read the table
The Topic keywords column summarizes the scientific content. The Historical / contextual note column is reserved for research groups, supervisor environments, trials, cohorts, or other historical context. The Verification status column distinguishes institutional records from entries that still require repository confirmation.
| Country | Year | Doctoral candidate | Title | University | Primary field | Secondary field | Scope | Topic keywords | Historical / contextual note | Link | Source type | DOI / ISBN | Verification status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Denmark | 2010 | Haseem Ashraf | Screening for Lung Cancer with low dose CT | University of Copenhagen / Gentofte University Hospital | Screening | Lung cancer screening, low-dose CT, DLCST (Danish Lung Cancer Screening Trial) | — | ||||||
| Denmark | 2012 | Zaigham Saghir | CT screening for lung cancer — the Danish Lung Cancer Screening Trial (DLCST) | University of Copenhagen / Gentofte University Hospital | Screening | Lung cancer LDCT screening, DLCST, stage shift, contamination, incidental findings, healthcare costs; Asger Dirksen / Jesper Holst Pedersen group | KU Research Portal | — | |||||
| Denmark | 2013 | Britta Weber | Identification of patients with non-small cell lung cancer responding to epidermal growth factor receptor targeting therapy | Aarhus University | Targeted therapy; Biomarkers | NSCLC, EGFR-targeting therapy, erlotinib, predictive biomarkers; Aarhus translational lung cancer group | AU PhD Day abstract | — | |||||
| Denmark | 2014 | Jakob Fraes Rasmussen | Psychosocial consequences and healthcare costs in lung cancer CT screening | University of Copenhagen | Screening; Supportive care / HRQoL | DLCST, psychosocial consequences, false positives, healthcare costs, registry study; Brodersen / Dirksen group | Region H Research Portal | — | |||||
| Denmark | 2015 | Morten Quist | EXHALE: Exercise intervention for patients with advanced lung cancer | University of Copenhagen / Copenhagen University Hospital | Supportive care / HRQoL | Advanced lung cancer, exercise, rehabilitation | — | ||||||
| Denmark | 2015 | Mathilde Marie Winkler Wille | Lung cancer screening — results from the Danish Lung Cancer Screening Trial with focus on high-risk profiling and pulmonary nodules | University of Copenhagen / Gentofte University Hospital | Screening; Imaging / Nodules | DLCST high-risk profiling, pulmonary nodule volumetry, PanCan model external validation, overdiagnosis; Asger Dirksen group | KU Research Portal | — | |||||
| Denmark | 2016 | Anne Winther Larsen | Genetic polymorphisms and FDG-PET/CT imaging as predictors of treatment response in non-small cell lung cancer patients treated with erlotinib | Aarhus University | Targeted therapy; Biomarkers | NSCLC, erlotinib, FDG-PET/CT, genetic polymorphisms, treatment-response prediction; Aarhus translational lung cancer group | AU Pure profile | — | |||||
| Denmark | 2016 | Birgitte Sandfeld-Paulsen | Biomarkers in non-small cell lung cancer: mRNA expression of the EGF system and exosome protein profiling | Aarhus University | Biomarkers | NSCLC biomarkers, EGF-system mRNA expression, exosome protein profiling; Aarhus translational lung cancer group | AU Newsroom | — | |||||
| Denmark | 2017 | Steffen Filskov Sørensen | Clinical impact of the Programmed Death Receptor-Ligand 1 pathway in patients with non-small cell lung cancer | Aarhus University | Immunotherapy; Biomarkers | NSCLC, PD-1/PD-L1 pathway, immune checkpoint biomarkers, clinical impact; Aarhus translational lung cancer group | AU Newsroom | — | |||||
| Denmark | 2017 | Laura Hohwü Thomsen | Emphysema and interstitial lung abnormalities in the Danish Lung Cancer Screening Trial | University of Copenhagen / Gentofte University Hospital | Screening; Pulmonary diagnostics | DLCST, emphysema progression on low-dose CT, interstitial lung abnormalities, smoker mortality; Asger Dirksen group | Region H Research Portal | — | |||||
| Denmark | 2018 | Christina Demuth | Erlotinib resistance and ctDNA monitoring in non-small cell lung cancer | Aarhus University | Targeted therapy; Biomarkers | NSCLC, EGFR TKI/erlotinib resistance, circulating tumour DNA monitoring; Aarhus translational lung cancer group | AU Newsroom | — | |||||
| Denmark | 2019 | Laura Ann Rechner | Advanced techniques to minimize side effects for patients treated with mediastinal radiotherapy | University of Copenhagen | Radiotherapy | Mediastinal radiotherapy, thoracic radiation toxicity | University of Copenhagen PDF | — | |||||
| Denmark | 2019 | Anne Tranberg Madsen | Applications of cell-free DNA in cancer — insights into biological variation and treatment monitoring | Aarhus University | Biomarkers | Cell-free DNA, biological variation, treatment monitoring, NSCLC; Aarhus translational lung cancer group | AU Newsroom | — | |||||
| Denmark | 2019 | Johanne Andersen Højbjerg | Circulating tumour DNA and microRNA in lung cancer | Aarhus University | Biomarkers | Lung cancer, ctDNA, circulating microRNA, liquid biopsy; Aarhus translational lung cancer group | AU press release (PDF) | — | |||||
| Denmark | 2019 | Johan Vad-Nielsen | Epithelial-mesenchymal transition and EGFR-TKI resistance in NSCLC — from in vitro induction to in vivo detection | Aarhus University | Targeted therapy; Translational biology | NSCLC, epithelial-mesenchymal transition, EGFR-TKI resistance, in vitro/in vivo translational models; Aarhus translational lung cancer group | AU press release (PDF) | — | |||||
| Denmark | 2020 | Eva Boysen Fynboe Ebert | Use of qPCR-based blood test for identification of response in patients with EGFR-mutated non-small cell lung cancer on systemic treatment | Aarhus University | Targeted therapy; Biomarkers | EGFR-mutated NSCLC, qPCR blood test, ctDNA, treatment-response monitoring; Aarhus translational lung cancer group | AU Newsroom | — | |||||
| Denmark | 2020 | Michelle S. Clement | Circulating biomarkers and resistance to tyrosine kinase inhibitors in solid cancer | Aarhus University | Targeted therapy; Biomarkers | Solid cancers (incl. NSCLC), circulating biomarkers, TKI resistance; Aarhus translational lung cancer group | AU press release (PDF) | — | |||||
| Denmark | 2022 | Morten Hornemann Borg | Early Detection of Lung Cancer: Biomarkers and CT Scans | Aalborg University | Screening; Biomarkers | Lung cancer early detection, blood-based biomarkers (EarlyCDT-Lung), CT thorax in Denmark, stage distribution, incidental findings; Weinreich/Hilberg group | VBN | 10.54337/aau504479984; ISBN 978-87-7573-814-4 | |||||
| Denmark | 2023 | Mette Thune Mouritzen | Learning from the past — optimizing future use of immune checkpoint inhibitors in advanced NSCLC | Aalborg University | Immunotherapy | Advanced NSCLC, immune checkpoint inhibitors, nationwide Danish cohort, PD-L1, 5-year survival; Carus/Ladekarl group | AAU | — | |||||
| Denmark | 2023 | Marie Tvilum Chadwick Hede | Investigating Response of Chemo-Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer | Aarhus University | Radiotherapy | Locally advanced NSCLC, adaptive radiotherapy, treatment response | Aarhus Pure | — | |||||
| Denmark | 2025 | Simone Stensgaard | Circulating biomarkers in advanced non-small cell lung cancer patients | Aarhus University | Biomarkers | Advanced NSCLC, circulating biomarkers, ctDNA, treatment monitoring; Aarhus translational lung cancer group | AU Pure | — | |||||
| Denmark | 2025 | Maiken Parm Ulhøi | Exploring EML4-ALK-positive non-small cell lung cancer in Denmark — clinical and molecular insights | Aarhus University | Targeted therapy; Molecular pathology | EML4-ALK NSCLC, ALK-rearranged lung cancer, clinical and molecular characterization, Danish cohort; Aarhus translational lung cancer group | AU Pure profile | — | |||||
| Finland | 2010 | Marius Crohns | Antioxidants, Cytokines and Markers of Oxidative Stress in Lung Cancer | Tampere University | Translational biology; Biomarkers | Lung cancer, oxidative stress, antioxidants, cytokines | TUNI portal | ISBN 978-951-44-7997-7 | |||||
| Finland | 2011 | Ilkka Ilonen | Non-small cell lung cancer — studies on pathogenesis, tumour targeting and treatment outcomes | University of Helsinki | Surgery; Translational biology | NSCLC pathogenesis, tumour targeting, surgical treatment outcomes | HELDA | ISBN 978-952-10-6953-6 | |||||
| Finland | 2014 | Kari J. Kurppa | ERBB4 mutations in cancer and amyotrophic lateral sclerosis | University of Turku | Targeted therapy; Translational biology | ERBB4 receptor tyrosine kinase, activating ERBB4 mutations in NSCLC, ALS; Elenius lab, Medical Biochemistry and Genetics. Postdoc 2016–2019 with Pasi Jänne, Dana-Farber; opponent Yosef Yarden (Weizmann) | UTUPub | Annales Universitatis Turkuensis D 1152; ISBN 978-951-29-5968-6 | |||||
| Finland | 2016 | Jenni Lahtela | Studying the functional relevance of lung cancer genetic drivers in their physiological niche | University of Helsinki | Translational biology | Lung cancer genetic drivers, physiological niche, translational mouse models, FIMM | UH HiLIFE | — | |||||
| Finland | 2016 | Satu Mäki-Nevala | Molecular markers in Finnish lung cancers | University of Helsinki | Molecular pathology | NSCLC molecular markers, EGFR/KRAS/BRAF/PIK3CA mutations, asbestos-related lung cancer | UH Research Portal | — | |||||
| Finland | 2017 | Johanna Mäkinen | Lung adenocarcinoma — histopathological features and their association with patient outcome | University of Oulu | Pathology / Histology | Lung adenocarcinoma, IASLC/ATS/ERS classification, growth patterns, histological prognostic features; Kaarteenaho group | OuluREPO | — | |||||
| Finland | 2020 | Juuso Paajanen | Prognostic factors in malignant pleural mesothelioma | University of Helsinki | Mesothelioma; Biomarkers | MPM, radiological/histopathological/clinical prognostic factors, long-term survivors | HELDA | ISBN 978-951-51-6339-4; PDF ISBN 978-951-51-6340-0 | |||||
| Finland | 2020 | Saana Andersson | Non-small cell lung cancer : studies on surgical treatment outcomes and prognostic factors | University of Helsinki | Surgery | NSCLC surgery, surgical treatment outcomes, prognostic factors | HELDA handle | URN:ISBN:978-951-51-5715-7 | |||||
| Finland | 2020 | Ville Rauma | Long-term quality of life in operated non-small cell lung cancer patients | University of Helsinki | Surgery; Supportive care / HRQoL | NSCLC surgery, long-term HRQoL, VATS vs thoracotomy, sleeve resection | HELDA PDF | ISBN 978-951-51-6088-1; PDF ISBN 978-951-51-6089-8 | |||||
| Finland | 2023 | Marika Koivu | Identification of predictive ERBB mutations for targeted treatment | University of Turku | Targeted therapy; Biomarkers | ERBB family receptor tyrosine kinases, NSCLC, predictive biomarkers, iSCREAM platform; opponent: Pasi Jänne | UTUPub | ISBN 978-951-29-9285-0 | |||||
| Finland | 2024 | Veera Ojala | ERBB4 as a potential therapeutic target in cancer | University of Turku | Targeted therapy; Translational biology | ERBB4 receptor tyrosine kinase, NSCLC and pan-cancer mutations, predictive biomarkers, pan-ERBB inhibitors; Elenius lab, Turku Bioscience Centre / Medical Biochemistry and Genetics | UTUPub | Annales Universitatis Turkuensis D 1812 | |||||
| Finland | 2024 | Topias Karjula | Treatment and histopathological prognostic factors of colorectal cancer pulmonary metastases | University of Oulu | Surgery; Pathology / Histology | Pulmonary metastases, thoracic surgery, CRC metastasectomy, immune microenvironment | OuluREPO | ISBN 978-952-62-4072-5; PDF ISBN 978-952-62-4073-2 | |||||
| Finland | 2026 | Ville Paappanen | Effectiveness of non-small cell lung cancer care in Finland | University of Eastern Finland (Kuopio) | Epidemiology; Diagnostic pathway | NSCLC, treatment effectiveness, real-world outcomes, operability | UEF eRepo | ISBN 978-952-61-5957-7; print/related ISBN 978-952-61-5956-0; URN:ISBN:978-952-61-5957-7 | |||||
| Iceland | 2017 | Guðrún Nína Óskarsdóttir | Outcomes following pulmonary resections for lung cancer in Iceland — survival in subgroups of patients | University of Iceland | Surgery; Epidemiology | Thoracic surgery, NSCLC resection, nationwide outcomes, elderly subgroups | Opin vísindi | — | |||||
| Iceland | 2022 | Gísli Þór Axelsson | Interstitial lung abnormalities and aging-related factors | University of Iceland | Imaging / Nodules | Interstitial lung abnormalities (ILA) on CT, aging biomarkers, AGES-Reykjavik cohort, relevance to nodule/screening incidental findings; Gunnar Guðmundsson group | Opin vísindi PDF | ISBN 978-9935-9657-3-8 | |||||
| Iceland | 2025 | Hrönn Harðardóttir | The role of the psychobiological stress response to a lung cancer diagnosis in tumor biology and survival (LUCASS) | University of Iceland | Translational biology; Supportive care / HRQoL | Lung cancer, psychobiological stress response, catecholamines, tumour biology, survival | Opin vísindi | — | |||||
| Norway | 2010 | Bjørn Henning Grønberg | Studies on chemotherapy and radiotherapy in non-small cell and small-cell lung cancer | NTNU (Norwegian University of Science and Technology) | Radiotherapy; Systemic therapy | NSCLC and SCLC, chemoradiotherapy, dose-escalated thoracic radiotherapy, randomised trials | NTNU | — | |||||
| Norway | 2010 | Samer Al-Saad | Prognostic impact of molecular markers related to tumor proliferation and differentiation in non-small-cell lung cancer | UiT The Arctic University of Norway (Tromsø) | Biomarkers; Pathology / Histology | NSCLC, tumour proliferation, differentiation markers, prognostic biomarkers; Tromsø lung cancer biomarker research environment | Sikt | — | |||||
| Norway | 2010 | Khalid Al-Shibli | The prognostic significance of the innate and adaptive immune systems in non-small cell lung carcinoma | UiT The Arctic University of Norway (Tromsø) | Immunotherapy; Biomarkers | NSCLC, innate immunity, adaptive immunity, tumour-infiltrating immune cells, prognostic biomarkers; Tromsø lung cancer biomarker research environment | Sikt | — | |||||
| Norway | 2011 | Sigve Andersen | Hypoxic markers and prognosis in non-small cell lung cancer (NSCLC) | UiT The Arctic University of Norway (Tromsø) | Biomarkers | NSCLC, tumour hypoxia, HIF-1α, CA-IX, prognostic biomarkers, TCRG | Sikt | — | |||||
| Norway | 2012 | Knut Skaug | Lung cancer on Haugalandet, Norway. A long-term follow-up study | University of Bergen | Epidemiology | Lung cancer outcomes, long-term follow-up, regional cohort | BORA UiB | — | |||||
| Norway | 2014 | Jo Steinson Stenehjem | Cancer incidence and occupational exposure in offshore oil industry workers | University of Oslo | Epidemiology | Occupational exposure, cancer incidence, lung cancer risk context | FHI PDF | — | |||||
| Norway | 2014 | Helge Stenvold | Angiogenic markers as prognostic factors in non-small cell lung cancer | UiT The Arctic University of Norway (Tromsø) | Biomarkers; Translational biology | NSCLC, angiogenic markers, VEGF-related pathways, prognostic biomarkers; Tromsø lung cancer biomarker research environment | Sikt | — | |||||
| Norway | 2016 | Maria Moksnes Bjaanæs | Molecular characterization of non-small cell lung cancer tumors | University of Oslo | Molecular pathology | NSCLC, molecular characterization, tumour profiling | UiO disputas | — | |||||
| Norway | 2016 | Camilla Sagerup | Epidemiological and molecular characteristics of lung cancer. Population-based and molecular studies. | University of Oslo | Epidemiology; Molecular pathology | Lung cancer epidemiology, molecular characteristics, population-based studies | UiO disputas | — | |||||
| Norway | 2016 | Lavina Ahmed | Axl as a biomarker in breast and lung cancer | University of Bergen | Biomarkers; Translational biology | AXL, breast and lung cancer, biomarker development, treatment resistance; CCBIO / BerGenBio industrial PhD environment | UiB CCBIO | — | |||||
| Norway | 2017 | Ann Rita Halvorsen | Circulating microRNAs; biomarkers for early detection, prediction of therapy response and prognosis in cancer patients | University of Oslo | Biomarkers | Circulating miRNAs, lung cancer biomarkers, early detection, therapy response, prognosis | UiO disputas | — | |||||
| Norway | 2017 | Tarje Halvorsen | Thoracic radiotherapy in limited disease small cell lung cancer | NTNU (Norwegian University of Science and Technology) | Radiotherapy | Limited-disease SCLC, hyperfractionated thoracic radiotherapy, THORA trial | Sikt | ISBN 978-82-326-2099-9 | |||||
| Norway | 2017 | Sigurd Mathiesen Hald | The prognostic impact of immune-related markers in non-small cell lung cancer | UiT The Arctic University of Norway (Tromsø) | Immunotherapy; Biomarkers | NSCLC, tumour-infiltrating lymphocytes, LAG-3, immune checkpoints, prognostic biomarkers, TCRG | Sikt | — | |||||
| Norway | 2017 | Erna-Elise Paulsen | Immunological markers in non-small cell lung cancer (NSCLC) | UiT The Arctic University of Norway (Tromsø) | Immunotherapy; Biomarkers | NSCLC, immune cell score, CD8+ TILs, TNM-Immunoscore, prognostic biomarkers; Tromsø lung cancer biomarker research environment | UiT disputas | — | |||||
| Norway | 2018 | Maria Paula Ramnefjell | Prognostic biomarkers and clinico-pathologic characteristics in non-small cell lung cancer — a study with special focus on tumour-vascular interactions | University of Bergen | Biomarkers; Pathology / Histology | NSCLC, prognostic biomarkers, tumour-vascular interactions | University of Bergen | — | |||||
| Norway | 2018 | Marius Lund-Iversen | Prognostic, diagnostic and predictive value of various proteins and mutations in lung carcinomas | University of Oslo | Molecular pathology; Biomarkers | Lung carcinomas, prognostic/diagnostic/predictive biomarkers, proteins and mutations | UiO disputation | — | |||||
| Norway | 2019 | Mehrdad Rakaee | Immune Infiltration and Clinical Outcome in Non-Small Cell Lung Cancer | UiT The Arctic University of Norway (Tromsø) | Immunotherapy; Pathology / Histology | NSCLC, multiplex IHC, macrophage phenotypes, tertiary lymphoid structures, immune cell score; Tromsø lung cancer biomarker research environment | UiT disputas | — | |||||
| Norway | 2019 | Marc McGowan | Drug-Resistance and Protective Factors in NSCLC | University of Oslo | Translational biology | NSCLC, drug resistance, protective factors | UiO disputation | — | |||||
| Norway | 2019 | Bjørg Sjøblom | Muscle measures in advanced non-small cell lung cancer: associations with survival and treatment toxicity | University of Oslo | Supportive care / HRQoL | Advanced NSCLC, skeletal muscle index and density, sarcopenia, chemotherapy toxicity | Sikt | — | |||||
| Norway | 2019 | Trine Stokstad | Timelines in lung cancer diagnostic workup | NTNU (Norwegian University of Science and Technology) | Diagnostic pathway | Lung cancer diagnostic pathways, time-to-treatment, quality indicators | Sikt | — | |||||
| Norway | 2020 | Hanne Astrid Eide | Serum and tumour biomarkers in non-small cell lung cancer | University of Oslo | Biomarkers | NSCLC, serum biomarkers, tumour biomarkers | UiO disputation | — | |||||
| Norway | 2020 | Are Kristensen | Quality of life in patients with advanced non-small cell lung cancer | NTNU (Norwegian University of Science and Technology) | Supportive care / HRQoL | Advanced NSCLC, health-related quality of life, end-of-life trajectory | NTNU PhD list | — | |||||
| Norway | 2020 | Christine Valan | Prognostic and predictive factors in limited stage small cell lung cancer | NTNU (Norwegian University of Science and Technology) | Biomarkers; Supportive care / HRQoL | LS-SCLC, prognostic and predictive factors, comorbidity, body composition | Sikt | — | |||||
| Norway | 2021 | Åsa Öjlert | The non-small cell lung cancer tumor immune microenvironment: implications for treatment and prognosis | University of Oslo | Immunotherapy; Biomarkers | NSCLC, tumour immune microenvironment, treatment response, prognosis | UiO disputation | — | |||||
| Norway | 2021 | Anne Heidi Skogholt | Identifying robust blood-based messenger RNA markers for potential detection of lung cancer | NTNU (Norwegian University of Science and Technology) | Biomarkers; Screening | Blood-based mRNA biomarkers, lung cancer detection, NLCB and HUNT biobanks | Sikt | — | |||||
| Norway | 2021 | Sissel Gyrid Freim Wahl | The prognostic value of KRAS in circulating cell-free DNA and tumor tissue in patients with non-small cell lung cancer | NTNU (Norwegian University of Science and Technology) | Biomarkers; Molecular pathology | NSCLC, KRAS mutations, cfDNA/ctDNA, prognostic biomarkers | NTNU Open | — | |||||
| Norway | 2023 | Astri Frafjord | Quantitative and qualitative analysis of immune cells in non-small cell lung cancer | University of Oslo | Immunotherapy; Translational biology | NSCLC, immune-cell analysis, tumour microenvironment | University of Oslo | — | |||||
| Norway | 2023 | Janna Berg | Pulmonary function and serum biomarkers in patients with non-small cell lung cancer, radiation pneumonitis and chronic obstructive lung disease | University of Oslo | Radiotherapy; Supportive care / HRQoL | NSCLC, radiation pneumonitis, COPD, pulmonary function, serum biomarkers | UiO disputation | — | |||||
| Norway | 2023 | Inger Johanne Z. Eide | Novel EGFR-directed therapy: a clinical study | University of Oslo | Targeted therapy | NSCLC, EGFR-directed therapy, clinical study | UiO disputation | — | |||||
| Norway | 2023 | Kristin Killingberg | Twice daily thoracic radiotherapy in limited stage small cell lung cancer | NTNU (Norwegian University of Science and Technology) | Radiotherapy | LS-SCLC, twice-daily thoracic radiotherapy, dose escalation, randomized phase II | NTNU | — | |||||
| Norway | 2023 | Anine Ottestad | Challenges in implementing circulating tumor DNA analyses in lung cancer research | NTNU (Norwegian University of Science and Technology) | Biomarkers | Lung cancer ctDNA, ultra-deep NGS, FDG-PET/CT correlations, prognostic biomarkers | Sikt | — | |||||
| Norway | 2023 | Kristin Stokke | Maintenance pemetrexed therapy in advanced non-small cell lung cancer | NTNU (Norwegian University of Science and Technology) | Systemic therapy | Advanced NSCLC, switch-maintenance pemetrexed, randomized phase III | Sikt | — | |||||
| Norway | 2024 | Austin James Rayford | Studies on the effect of AXL inhibition in non-small cell lung cancer | University of Bergen | Targeted therapy; Immunotherapy | NSCLC, AXL inhibition, immune-checkpoint inhibitor resistance, bemcentinib, tumour microenvironment; CCBIO / BerGenBio industrial PhD environment | UiB CCBIO | — | |||||
| Norway | 2024 | Gustav Graabak | Radiotherapy in lung cancer | NTNU (Norwegian University of Science and Technology) | Radiotherapy; Epidemiology | Lung cancer radiotherapy, population-based patterns of care, LS-SCLC thoracic radiotherapy | NTNU PhD list | — | |||||
| Sweden | 2010 | Luigi De Petris | Discovery and validation of protein biomarkers for lung cancer | Karolinska Institutet | Biomarkers | Lung cancer protein biomarkers, diagnosis, prognosis | KI Open Archive | 10.69622/26907079 | |||||
| Sweden | 2011 | Andrea Koch | Clinical Aspects of Inflammation in Non-small Cell Lung Cancer | Linköping University | Biomarkers; Translational biology | NSCLC, systemic inflammation, COX-2, prognostic markers | DiVA PDF | Linköping University Medical Dissertations 1232 | |||||
| Sweden | 2015 | Karin Lindberg | Stereotactic body radiation therapy of primary lung cancer and metastases | Karolinska Institutet | Radiotherapy | SBRT, central lung tumours, foundation work for the HILUS trial | KI Open Archive | hdl.handle.net/10616/44636; ISBN 978-91-7549-942-0 | |||||
| Sweden | 2016 | Ghazaleh Efazat | Ephrin and Eph-receptor growth factor signaling in non-small cell lung cancer: identification of biomarkers and therapeutic targets | Karolinska Institutet | Translational biology; Biomarkers | NSCLC biomarkers, therapeutic targets, Eph/ephrin signalling | KI Open Archive | ISBN 978-91-7676-285-1 | |||||
| Sweden | 2017 | Ghazal Heidari Hamedani | Syndecan-1 insights in mesothelioma | Karolinska Institutet | Mesothelioma; Translational biology | Malignant mesothelioma, syndecan-1, tumour biology | KI Open Archive | 10.69622/26920003 | |||||
| Sweden | 2018 | Anna F Karlsson | Genomic characterization of non-small cell lung cancer | Lund University | Molecular pathology | NSCLC genomics, fusion gene detection, treatment-predictive mutation testing | LUP | — | |||||
| Sweden | 2019 | Sofi Isaksson | Blood and tumor-based analyses for improved prognostics in lung cancer | Lund University | Biomarkers | Lung cancer prognostics, ctDNA, serum tumour markers, mutation analysis | LUP | — | |||||
| Sweden | 2020 | Samuel Kvarnbrink | LRIG1 in lung cancer — prognostic effects and mechanistic studies | Umeå University | Biomarkers; Translational biology | NSCLC, LRIG1 prognostic biomarker, EGFR pathway, LMO7/LIMCH1 interactions, early-stage NSCLC; Mikael B Johansson group | DiVA | Umeå University medical dissertations 2108 | |||||
| Sweden | 2020 | Georgios Tsakonas | Biomarkers for CNS metastasis in non-small cell lung cancer (NSCLC) | Karolinska Institutet | Biomarkers | NSCLC, brain metastases, biomarkers | KI Open Archive | hdl.handle.net/10616/47421 | |||||
| Sweden | 2020 | Anna-Karin Wennstig | Long-term side effects of radiotherapy in breast cancer — studies in ischemic heart disease and lung cancer | Umeå University | Radiotherapy; Epidemiology | Adjuvant breast cancer radiotherapy, second primary lung cancer risk, ischemic heart disease, BCBaSe registry; Mikael B Johansson co-author | DiVA | Umeå University medical dissertations 2069 | |||||
| Sweden | 2022 | Annette Salomonsson | Molecular characterization of lung cancer | Lund University | Molecular pathology | NSCLC molecular characterization, EGFR alterations, prognostic markers | LUP | — | |||||
| Sweden | 2022 | Vitali Grozman | SBRT of large tumors and tumors located near organs at risk in the thoracic cavity | Karolinska Institutet | Radiotherapy | SBRT, ultracentral lung tumours, organs-at-risk, HILUS trial dosimetry | KI Open Archive | hdl.handle.net/10616/47886 | |||||
| Sweden | 2023 | Johan Isaksson | The Molecular Epidemiology of Non-Small Cell Lung Cancer | Uppsala University | Biomarkers; Molecular pathology | NSCLC biomarkers, systemic inflammation, plasma proteomics, KRAS G12C, chemoradiotherapy outcomes; Patrick Micke / Johan Botling group | DiVA | — | |||||
| Sweden | 2023 | Linda Willén | Factors influencing management and outcome in non-small cell lung cancer — the role of socioeconomic status, age, geographic region of origin and aspects of quality of life | Umeå University | Epidemiology; Supportive care / HRQoL | NSCLC equity-of-care, LCBaSe registry, education/SES, age, immigrant status, HRQoL; Mikael B Johansson group | DiVA | — | |||||
| Sweden | 2024 | Hedvig Elfving | Improving the diagnostic armamentarium of lung cancer | Uppsala University | Pathology / Histology; Biomarkers | NSCLC diagnostic biomarkers, targeted therapy, immunotherapy, immunohistochemistry; Patrick Micke group | DiVA | — | |||||
| Sweden | 2024 | Deborah Figueiredo Nacer de Oliveira | Decoding pan-cancer complexity | Lund University | Translational biology; Molecular pathology | Pan-cancer multiomics, lung and breast, gene-expression prognostic predictors | LUP | — | |||||
| Sweden | 2024 | Mohammed S. I. Mansour | Biomarkers in mesothelioma and non-small cell lung cancer | Lund University | Pathology / Histology; Mesothelioma | Mesothelioma, NSCLC, cytology cell blocks, PD-L1, immunohistochemistry | LUP | — | |||||
| Sweden | 2024 | Erik Sachs | Surgical treatment of lung cancer | Karolinska Institutet | Surgery; Epidemiology | Thoracic surgery, VATS, sex/income disparities, outcomes | KI Open Archive | 10.69622/26897305 | |||||
| Sweden | 2024 | Marcus Skribek | Strategies for optimizing immune checkpoint inhibition in advanced non-small cell lung cancer | Karolinska Institutet | Immunotherapy | NSCLC, immune checkpoint inhibition, treatment optimization | KI Open Archive | 10.69622/26894053 | |||||
| Sweden | 2025 | Tina Becirovic | Lung cancer metabolism: from molecular mechanisms to translational studies | Karolinska Institutet | Translational biology | NSCLC metabolism, BACH1, deubiquitinating enzymes, translational biology | KI Open Archive | 10.69622/28367612 | |||||
| Sweden | 2025 | Olena Berkovska | Harnessing proteomics for precision medicine in lung cancer | Karolinska Institutet | Biomarkers | Lung cancer proteomics, precision medicine, biomarkers | KI Open Archive | 10.69622/28563788 | |||||
| Sweden | 2025 | Sara Lindberg | Developments of stereotactic body radiotherapy in the metastatic setting and for central lung tumors | Karolinska Institutet | Radiotherapy | Expanded HILUS pooled analysis, SBRT toxicity, oligometastatic SBRT | KI Open Archive | 10.69622/28625063 | |||||
| Sweden | 2025 | Ella Äng Eklund | Precision medicine in Non-Small Cell Lung Cancer, with a focus on KRAS-mutations | University of Gothenburg | Targeted therapy; Immunotherapy | NSCLC, KRAS mutations, immunotherapy biomarkers, aging and tumour progression; Sahlgrenska Academy | GUPEA PDF | — | |||||
| Sweden | 2026 | Louise Mövik | Risk models for radiotherapy of lung cancer | University of Gothenburg | Radiotherapy | Lung cancer radiotherapy, dose–response models, early respiratory mortality, automated data preparation; Sahlgrenska Academy | GUPEA | — |
Suggested maintenance practice: verify repository links periodically, prefer persistent identifiers such as DOI, ISBN, URN, Handle, or institutional repository records, and avoid using person-profile pages as final sources when a thesis record is available.
Research routes
Explore the research overview, current projects, collaboration routes, and expert network.